Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Assembly Biosciences (ASMB) over the last 8 years, with Sep 2025 value amounting to $171.9 million.

  • Assembly Biosciences' Cash from Financing Activities was N/A to $171.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.2 million, marking a year-over-year change of. This contributed to the annual value of $29.4 million for FY2024, which is 113.12% up from last year.
  • As of Q3 2025, Assembly Biosciences' Cash from Financing Activities stood at $171.9 million, which was up 48,060.22% from $357,000 recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Cash from Financing Activities peaked at $171.9 million during Q3 2025, and registered a low of $134,000 during Q2 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $6.8 million (2023), whereas its average is $27.2 million.
  • As far as peak fluctuations go, Assembly Biosciences' Cash from Financing Activities soared by 28,586.55% in 2021, and later slumped by 97.13% in 2025.
  • Assembly Biosciences' Cash from Financing Activities (Quarterly) stood at $2.7 million in 2021, then slumped by 83.89% to $437,000 in 2022, then soared by 2,003.43% to $9.2 million in 2023, then skyrocketed by 84.89% to $17.0 million in 2024, then tumbled by 97.13% to $171.9 million in 2025.
  • Its Cash from Financing Activities was $171.9 million in Q3 2025, compared to $357,000 in Q2 2025 and $1.9 million in Q1 2025.